Citations

Showing 10 of 108083 citations.

A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors
Lehrer, Eric J. , Sindhu, Kunal K. , Dickstein, Daniel R. , Cohen, Mira, Lazarev, Stanislav , Quiñones‐Hinojosa, Alfredo , Green, Sheryl , Sindhu, Kunal K , Dickstein, Daniel R , Jones, Brianna M. , Trifiletti, Daniel M.

Mayo Clinic

Biomedicines | November 21, 2022 | Volume: 10 | Issue: 11 | Pages: 2977

10.3390/biomedicines10112977 | PMID 36428546 Get It

Stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICIs) are widely used in the management of brain metastases. These therapies are commonly administered concurrently; as SRS may enhance anti-tumor immunity and responsiveness to ICIs. However, the use of ICIs with and without SRS in the management of primary brain tumors remains a controversial topic. Meningiomas are the most common nonmalignant and extra-parenchymal brain tumor, which often respond well to surgery and radiotherapy. However, higher grade meningiomas tend to be resistant to these treatments, and the use of chemotherapy and targeted agents in this setting have yielded disappointing results. Thus, there is heightened interest in the utilization of ICIs. Glioblastoma is the most common malignant primary intraparenchymal brain tumor. It is associated with a grim prognosis with a median overall survival of approximately 20 months, despite optimal therapy. While SRS in the adjuvant setting, and ICI in the recurrent setting, have failed to demonstrate a survival benefit, SRS in the preoperative setting has the potential to enhance anti-tumor immunity and responsiveness to ICIs. Thus, these treatments represent an attractive option to add to the armamentarium of meningioma and glioblastoma management. In this review, we provide a detailed overview of the evidence supporting the use of ICIs and SRS in each of these settings.
Automated Detection of Surgical Implants on Plain Knee Radiographs Using a Deep Learning Algorithm
Kim, Back , Lee, Do Weon , Lee, Sanggyu , Ko, Sunho , Jo, Changwung , Park, Jaeseok , Choi, Byung Sun , Krych, Aaron J. , Pareek, Ayoosh , Han, Hyuk‐Soo , Ro, Du Hyun , Krych, Aaron J

Mayo Clinic

Medicina | November 21, 2022 | Volume: 58 | Issue: 11 | Pages: 1677

10.3390/medicina58111677 | PMID 36422216 Get It

Background and Objectives: The number of patients who undergo multiple operations on a knee is increasing. The objective of this study was to develop a deep learning algorithm that could detect 17 different surgical implants on plain knee radiographs. Materials and Methods: An internal dataset consisted of 5206 plain knee antero-posterior X-rays from a single, tertiary institute for model development. An external set contained 238 X-rays from another tertiary institute. A total of 17 different types of implants including total knee arthroplasty, unicompartmental knee arthroplasty, plate, and screw were labeled. The internal dataset was approximately split into a train set, a validation set, and an internal test set at a ratio of 7:1:2. You Only look Once (YOLO) was selected as the detection network. Model performances with the validation set, internal test set, and external test set were compared. Results: Total accuracy, total sensitivity, total specificity value of the validation set, internal test set, and external test set were (0.978, 0.768, 0.999), (0.953, 0.810, 0.990), and (0.956, 0.493, 0.975), respectively. Means ± standard deviations (SDs) of diagonal components of confusion matrix for these three subsets were 0.858 ± 0.242, 0.852 ± 0.182, and 0.576 ± 0.312, respectively. True positive rate of total knee arthroplasty, the most dominant class of the dataset, was higher than 0.99 with internal subsets and 0.96 with an external test set. Conclusion: Implant identification on plain knee radiographs could be automated using a deep learning technique. The detection algorithm dealt with overlapping cases while maintaining high accuracy on total knee arthroplasty. This could be applied in future research that analyzes X-ray images with deep learning, which would help prompt decision-making in clinics.
Impact of the COVID ‐19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race
Berrian, Jennifer L. , Ezenwajiaku, Nkiruka, Moreno‐Aspitia, Alvaro , Toriola, Adetunji T. , Colditz, Graham A. , Housten, Ashley J. , Hall, Lannis, Fiala, Mark A. , Holton, Sara J, Toriola, Adetunji T , Colditz, Graham A , Housten, Ashley J , Ademuyiwa, Foluso O , Fiala, Mark A , Liu, Ying , Holton, Sara J., Ademuyiwa, Foluso O.

Mayo Clinic

Cancer Medicine | November 21, 2022 | Volume: 12 | Issue: 6 | Pages: 7381-7388

10.1002/cam4.5439 | PMID 36404491 Get It

Abstract Purpose To determine if the COVID‐19 pandemic has further exacerbated racial disparities in late‐stage presentation of breast, colorectal, lung, and prostate cancers. Methods We conducted a registry‐based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019–June 2019 (pre‐COVID‐19) and March 2020–June 2020 (early‐COVID‐19). We compared the volume of new diagnoses and stage at presentation according to race between both periods. Results During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre‐COVID‐19 period included 2120 (64.2%), and the early‐COVID‐19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre‐COVID‐19, 16.8% were diagnosed with metastatic disease, versus 20.4% early‐COVID‐19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non‐significant proportional decline of 1.9% in Black patients diagnosed with non‐metastatic breast, colorectal, lung, and prostate cancers early‐COVID‐19 ( p = 0.71) and a non‐significant proportional increase of 7% in Black patients diagnosed with metastatic disease ( p = 0.71). Difference‐in‐difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients. Conclusion While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID‐19 pandemic, the impact was similar for White and Black patients.
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
Mangaonkar, Abhishek A. , Langer, Kimberly J., Finke, Christy M. , Litzow, Mark R. , Shah, Meera , Bartoo, Gabriel , Kutzke, Jade L. , Samec, Matthew J. , Reichard, Kaaren K. , Olteanu, Horatiu , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Lasho, Terra L. , Litzow, Mark R. , Shah, Mithun V , Kutzke, Jade, McCullough, Kristen B , Koster, Matthew, Samec, Matthew, Patnaik, Mrinal , Alkhateeb, Hassan B , Hogan, William J. , Go, Ronald S. , McCullough, Kristen , Koster, Matthew J. , Warrington, Kenneth J. , Riwes, Mary

Mayo Clinic

American Journal of Hematology | November 20, 2022 | Volume: 98 | Issue: 2 | Pages: No page available

10.1002/ajh.26786 | PMID 36403135 Get It

Low-Dose ACTH Stimulation Test in Obesity: A Randomized Dose Assessment
Mancillas‐Adame, Leonardo , Sánchez‐García, Adriana , Rodríguez‐Gutiérrez, René , Gonzalez‐Velazquez, Camilo , Lavalle‐González, Fernando J. , Zuñiga-Hernández, Jorge A , Rios-Ortega, Adriana Gabriela , González‐González, José Gerardo , Mancillas-Adame, Leonardo G , Lavalle-Gonzalez, Fernando Javier , González-González, José Gerardo , Zuñiga-Hernandez, Jorge Alberto , González-Velázquez, Camilo , Sánchez-García, Adriana

Mayo Clinic

International Journal of Endocrinology | November 19, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-5

10.1155/2022/7860272 | PMID 36457351 Get It

Background. The short cosyntropin test is widely used for adrenal insufficiency screening and diagnosis. Lower cosyntropin doses may have greater sensitivity vs. the standard dose in detecting adrenal dysfunction. Obesity and overweight are increasing, impacting the clinical presentation of some diseases. Currently more than 50% of the subjects diagnosed with autoimmune adrenal insufficiency have a BMI greater than 25, and hence individuals living with overweight and obesity are more frequently requiring evaluation of the adrenal cortical function. Fixed-dose cosyntropin stimulation may not be appropriate for individuals with obesity. Objective. The primary objective was to compare cortisol response to a weight-adapted cosyntropin dose vs. a fixed low dose (1 µg) and a more physiologically fixed dose (10 µg). Methods. Twenty individuals with obesity and 20 age-matched healthy controls underwent in a randomized sequence at least one-week apart, to the The short cosyntropin test with three different doses, 0.2 µg/kg of body weight, 1 or 10 µg fixed dose stimuli. The assessment and data analysis were blinded to the individual and the investigator. Results. Cortisol response was reduced in the group with obesity with the 1 µg fixed dose stimuli at 30 minutes (median, IQR) 649.6 µg, 567.3–738.4 µg for the control group vs. 568.6 µg, 528.4–623.13 µg, p = 0.04 ; there was a lower cortisol peak at 60′ in all the three evaluated doses, with a dose-dependent trend. A weight-adapted cosyntropin dose of 0.2 µg in obesity produces a similar response to the one observed in individuals without obesity. The 1 µg ACTH test falls short on stimulating the cortisol adrenal response in individuals with obesity.
The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
Safdar, Nasia , Khanna, Sahil , Khanna, S , Seekatz, Anna Maria

Mayo Clinic

Therapeutic Advances in Gastroenterology | November 19, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221134396 | PMID 36425405 Get It

The species composition of the human gut microbiota is related to overall health, and a healthy gut microbiome is crucial in maintaining colonization resistance against pathogens. Disruption of gut microbiome composition and functionality reduces colonization resistance and has been associated with several gastrointestinal and non-gastrointestinal diseases. One prime example is Clostridioides difficile infection (CDI) and subsequent recurrent infections that occur after the development of systemic antibiotic-related dysbiosis. Standard-of-care antibiotics used for both acute and recurrent infections do not address dysbiosis and often worsen the condition. Moreover, monoclonal antibodies, recommended in conjunction with standard-of-care antibiotics for the prevention of recurrent CDI in patients at high risk of recurrence, reduce recurrences but do not address the underlying dysbiosis. Fecal microbiota transplantation (FMT) is an evolving therapeutic strategy in which microbes are harvested from healthy donor stool and transplanted into the gut of a recipient to restore the gut microbiome. Although effective in the prevention of recurrent CDI, some existing challenges include screening and the standardization of stool acquisition and processing. Recent safety alerts by the US Food and Drug Administration raised concern about the possibility of transmission of multidrug-resistant organisms or severe acute respiratory syndrome coronavirus 2 via FMT. Increased knowledge that microbes are beneficial in restoring the gut microbiome has led to the clinical development of several newer biotherapeutic formulations that are more regulated than FMT, which may allow for improved restoration of the gut microbiome and prevention of CDI recurrence. This review focuses on mechanisms by which gut microbiome restoration could influence colonization resistance against the pathogen C. difficile. Plain language summary The Role of the Gut Microbiome in Clostridioides difficile Infection Introduction: A rich and diverse gut microbiome is key to immune system regulation and colonization resistance against pathogens. A disruption in the gut microbiome composition can make the gut more vulnerable to diseases such as Clostridioides difficile infection (CDI), caused by the bacterium C. difficile. CDI management presents a therapeutic dilemma, as it is usually treated with antibiotics that can treat the infection but also can damage the microbiome. Treatment of CDI using antibiotics can further reduce microbial diversity and deplete beneficial bacteria from the gut leading to a condition called dysbiosis. Antibiotic treatment can be followed by therapies that restore the gut microbiota, boost colonization resistance, and prevent the development of antimicrobial resistance. It is important to evaluate treatment options to determine their safety and effectiveness. Methods: The researchers provided an overview of the mechanisms that the gut microbiome uses to prevent colonization of the gut by pathogens. They subsequently reviewed the efficacy and shortcomings of the following treatments for CDI: - Antibiotics - Monoclonal antibodies - Fecal microbiota transplantation (FMT) Results: Commensal intestinal bacteria prevent colonization of the gut by pathogens using mechanisms such as: - Competition for key nutrients - Production of inhibitory bile acids - Short-chain fatty acid production - Lowering the luminal pH - Production of bacteriocins Antibiotic therapy is recommended as a standard treatment for CDI. However, patients are vulnerable to recurrent CDI after discontinuation of the therapy. Monoclonal antibodies that inactivate C. difficile toxins may be recommended along with antibiotics to prevent recurrent CDI. However, this approach does not restore the microbiome. FMT is one method of microbial restoration, where stool is harvested from a healthy donor and transplanted into a patient’s colon. Although FMT has shown some efficacy in the treatment of recurrent CDI, the procedure is not standardized. Safety concerns have been raised about the possibility of transmission of multidrug-resistant pathogens via FMT. Conclusion: Treatment methods that can efficiently restore the diversity of the gut microbiome are crucial in preventing recurrence of CDI.
Impact of Chronic Kidney Disease on In-Hospital Outcomes of Hospitalizations With Acute Limb Ischemia Undergoing Endovascular Therapy
Patel, Harsh , Decter, Dean , Narayanan, Mahesh Anantha , Kumar, Ashish , Sheth, Aakash , Patel, Bhavin , Patel, Toralben , Devani, Hiteshkumar, Shah, Vrushali, Doshi, Preet, Patel, Smit, Adalja, Devina , Vallabhajosyula, Saraschandra , Kumar, Ashish , Patel, Bhavin A , Doshi, Rajkumar P , Vallabhajosyula, Saraschandra , Thakkar, Samarthkumar , Zahid, Salman , Shah, Vrushali, Shariff, Mariam , Doshi, Rajkumar

Mayo Clinic

Journal of Endovascular Therapy | November 19, 2022 | Volume: 31 | Issue: 4 | Pages: 606-614

10.1177/15266028221134887 | PMID 36401519 Get It

Purpose: Studies on outcomes related to endovascular treatment (EVT) in advanced stages of chronic kidney disease (CKD) and end-stage renal disease (ESRD) among hospitalizations with acute limb ischemia (ALI) are limited. Methods: The Nationwide Inpatient Sample was quarried from October 2015 to December 2017 to identify the hospitalizations with ALI and undergoing EVT. The study population was subdivided into 3 groups based on their CKD stages: group 1 (No CKD, stage I, stage II), group 2 (CKD stage III, stage IV), and group 3 (CKD stage V and ESRD). The primary outcome was all-cause in-hospital mortality. Results: A total of 51 995 hospitalizations with ALI undergoing EVT were identified. The in-hospital mortality was significantly higher in group 2 (OR = 1.17; 95% CI 1.04 – 1.32, p=0.009) and group 3 (OR = 3.18; 95% CI 2.74–3.69, p<0.0001) compared with group 1. Odds of minor amputation, vascular complication, atherectomy, and blood transfusion were higher among groups 2 and 3 compared with group 1. Group 2 had higher odds of access site hemorrhage compared with groups 1 and 3, whereas group 3 had higher odds of major amputation, postprocedural infection, and postoperative hemorrhage compared with groups 1 and 2. Besides, groups 2 and 3 had lower odds of discharge to home compared with group 1. Finally, the length of hospital stay and cost of care was significantly higher with the advancing CKD stages. Conclusion: Advanced CKD stages and ESRD are associated with higher mortality, worse in-hospital outcomes and higher resource utilization among ALI hospitalizations undergoing EVT. Clinical Impact Current guidelines are not clear for the optimum first line treatment of acute limb ischemia, especially in patients with advanced kidney disease as compared to normal/mild kidney disease patients. We found that advanced kidney disease is a significant risk factor for worse in-hospital morbidity and mortality. Furthermore, patients with acute limb ischemia and advanced kidney disease is associated with significantly higher resource utilization as compared to patients with normal/mild kidney disease. This study suggests shared decision making between treating physician and patients when considering endovascular therapy for the treatment of acute limb ischemia in patients with advanced kidney disease.
Valvular Heart Disease: New Concepts in Pathophysiology and Therapeutic Approaches
Eleid, Mackram F. , Nkomo, Vuyisile T. , Pislaru, Sorin V. , Gersh, Bernard J.

Mayo Clinic

Annual Review of Medicine | November 19, 2022 | Volume: 74 | Issue: 1 | Pages: 155-170

10.1146/annurev-med-042921-122533 | PMID 36400067 Get It

This review discusses recent advancements in the field of valvular heart disease. Topics covered include recognition of the impact of atrial fibrillation on development and assessment of valvular disease, strategies for global prevention of rheumatic heart disease, understanding and management of secondary mitral regurgitation, the updated classification of bicuspid aortic valve disease, recognition of heightened cardiovascular risk associated with moderate aortic stenosis, and a growing armamentarium of transcatheter therapies.
Advanced cross-sectional imaging of cerebral aneurysms
Diab, Rawan, Chang, Dandan, Levitt, Michael R. , Aksakal, Mehmet , Zhao, Huilin , Romero-Sánchez, Griselda , Mossa‐Basha, Mahmud , Huynh, Thien J, Mossa-Basha, Mahmud , Levitt, Michael R , Chang, Dandan, Zhu, Chengcheng , Huynh, Thien

Mayo Clinic

The British Journal of Radiology | November 18, 2022 | Volume: 96 | Issue: 1141 | Pages: No page available

10.1259/bjr.20220686 | PMID 36400095 Get It

While the rupture rate of cerebral aneurysms is only 1% per year, ruptured aneurysms are associated with significant morbidity and mortality, while aneurysm treatments have their own associated risk of morbidity and mortality. Conventional markers for aneurysm rupture include patient-specific and aneurysm-specific characteristics, with the development of scoring systems to better assess rupture risk. These scores, however, rely heavily on aneurysm size, and their accuracy in assessing risk in smaller aneurysms is limited. While the individual risk of rupture of small aneurysms is low, due to their sheer number, the largest proportion of ruptured aneurysms are small aneurysms. Conventional imaging techniques are valuable in characterizing aneurysm morphology; however, advanced imaging techniques assessing the presence of inflammatory changes within the aneurysm wall, hemodynamic characteristics of blood flow within aneurysm sacs, and imaging visualization of irregular aneurysm wall motion have been used to further determine aneurysm instability that otherwise cannot be characterized by conventional imaging techniques. The current manuscript reviews conventional imaging techniques and their value and limitations in cerebral aneurysm characterization, and evaluates the applications, value and limitations of advanced aneurysm imaging and post-processing techniques including intracranial vessel wall MRA, 4D-flow, 4D-CTA, and computational fluid dynamic simulations.
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
Okuda, Darin T. , Kantarci, Orhun H. , Sormani, Maria Pia , Azevedo, Christina , Hua, Le H. , Hotermans, Christophe, Mendoza, Jason P. , Walsh, John, Hehn, Christian von, Vargas, Wendy , Donlon, Stacy, Okai, Annette , Sıva, Aksel , Pelletier, Daniel , Kantarci, OH , Sormani, Maria P , Mendoza, Jason , Stüve, Olaf , Siva, Aksel , Okuda, Darin T , Lebrun‐Frénay, Christine , Bovis, Francesca , Amezcua, Lilyana , Mowry, Ellen M. , Naismith, Robert T. , Pardo, Gabriel , Repovic, Pavle

Mayo Clinic

Annals of Neurology | November 18, 2022 | Volume: 93 | Issue: 3 | Pages: 604-614

10.1002/ana.26555 | PMID 36401339 Get It

Objective The radiologically isolated syndrome (RIS) represents the earliest detectable pre‐clinical phase of multiple sclerosis (MS). This study evaluated the impact of therapeutic intervention in preventing first symptom manifestation at this stage in the disease spectrum. Methods We conducted a multi‐center, randomized, double‐blinded, placebo‐controlled study involving people with RIS. Individuals without clinical symptoms typical of MS but with incidental brain MRI anomalies consistent with central nervous system (CNS) demyelination were included. Within 12 MS centers in the United States, participants were randomly assigned 1:1 to oral dimethyl fumarate (DMF) 240 mg twice daily or placebo. The primary endpoint was the time to onset of clinical symptoms attributable to a CNS demyelinating event within a follow‐up period of 96 weeks. An intention‐to‐treat analysis was applied to all participating individuals in the primary and safety investigations. The study is registered at ClinicalTrials.gov , NCT02739542 (ARISE). Results Participants from 12 centers were recruited from March 9, 2016, to October 31, 2019, with 44 people randomized to dimethyl fumarate and 43 to placebo. Following DMF treatment, the risk of a first clinical demyelinating event during the 96‐week study period was highly reduced in the unadjusted Cox proportional‐hazards regression model (hazard ratio [HR] = 0.18, 95% confidence interval [CI] = 0.05–0.63, p = 0.007). More moderate adverse reactions were present in the DMF (34 [32%]) than placebo groups (19 [21%]) but severe events were similar (DMF, 3 [5%]; placebo, 4 [9%]). Interpretation This is the first randomized clinical trial demonstrating the benefit of a disease‐modifying therapy in preventing a first acute clinical event in people with RIS. ANN NEUROL 2023;93:604–614